Registration, masks, badge, 6 posters (🙏👍🎊 my superstar pharmacy team) and 4 CIBMTR proposals up for voting (🙏 mentors and collaborators). I am ready for my favorite meeting of the year! ASTCT CIBMTR #Tandem22 MUSC Hollings Cancer Center James Davis, PharmD, BCOP Mary McGann @KGaffneyPharmD

Poster #3 Early and more frequent use of tocilizumab and steroids is both effective & safe for post CAR CRS and ICANS Check out poster #236 showing MUSC early vs standard CAR T toxicity management protocol at #Tandem22 ASTCT 👌👍🎊@KGaffneyPharmD MUSC Hollings Cancer Center MUSC Pharmacy Residency

Poster #4 Organ failure/ complications post CAR T cell therapy are mild and reversible except in the case of ICANS Check out our poster#233 on Post CAR T organ complications at #Tandem22 ASTCT 👌🎊👍Mary McGann MUSC Hollings Cancer Center MUSC Pharmacy Residency

Come chat about cytopenias post-CAR T! I’m interested to hear other institutions experiences too #Tandem22

Proud to be part of the team MUSC Hollings Cancer Center with 5 posters describing our experiences with CAR T 🎉🤓👍🏼#Tandem22 ASTCT James Davis, PharmD, BCOP @hamzahashmi87 @KGaffneyPharmD

We snuck in a beautiful hike in #SLC before we head back tomorrow. Living the dream ASTCT #tandem22 with Mary McGann and @hamzahashmi87

Anakinra may be an alternative to tocilizumab for cytokine release syndrome after initial management with the latter agent, which continues to be in short supply. pharmacypracticenews.com/Clinical/Artic… Mary McGann

Happy to share our new paper comparing Ide-cel vs Cilta-cel. strong work @hamzahashmi87 Mary McGann Abigail Shockley MUSC Pharmacy Residency #mmsm #oncopharm working link here: tandfonline.com/doi/full/10.10…

And this is why I love CAR T!

CAR T is an ever-evolving field! Here we discuss our experiences with outpatient monitoring and opportunities for optimization MUSC Hollings Cancer Center Transplantation and Cellular Therapy Journal @hamzahashmi87 Kathy @KGaffneyPharmD James Davis, PharmD, BCOP Deidra Smith doi.org/10.1016/j.jtct…

🚨 The fludarabine shortage is getting worse. Centers shouldn’t have to figure out alternative plans for transplant patients (#bmt) and CAR-T (#CARTCell). Many centers weren’t prepared for this-we have been lucky so far-but what’s next? ASTCT U.S. FDA ASHP

🚨 💉💉😷😷🚨 Humbled to publish our new paper in @BloodJournal #evusheld #MedTwitter #IDTwitter #oncopharm 🤙🏼🤙🏼Proud of our team Katelynn Granger, PharmD, BCOP Deidra Smith Mary McGann @hamzahashmi87 @KGaffneyPharmD MUSC Pharmacy Residency MUSC Research MUSC Hollings Cancer Center

Does the addition of daratumumab to RVd induction impact stem cell collection? We shed some light on this question in our latest ASTCT article. once again, great work team! 👏 @hamzahashmi87 Kiera Roubal, PharmD, BCOP Deidra Smith @KGaffneyPharmD Mary McGann #mmsm sciencedirect.com/science/articl…

Muhammad Kashif Amin, MD interviewing William Wesson who is presenting his work on CART toxicity, REMS and how it interplay’s with access

Phenomenal session on Cytopenias post CAR T— US and UK perspective at the Pharmacy Track #Tandem24 ASTCT Mary McGann

A great collaboration! #Tandem24 #EBMT2024

If you or your student, resident, fellow need a quick refresher on how to manage #BCMA associated cytopenias, aka #ICAHT, please check out our new article below.. #mmsm Mary McGann Jessie Marini Hamza Hashmi #oncopharm tandfonline.com/doi/full/10.10…